Supplementary materials

1: Update on International Committee on Taxonomy of Viruses (ICTV); Current ICTV Taxonomy Release | ICTV (https://ictv.global/taxonomy)

2: 2021 Update on Laboratory Biosafety Manual; WHO publishes the latest manual on biosafety in laboratories (https://www.who.int/news/item/14-01-2021-who-publishes-latest-manual-on-biosafety-in-laboratories)

3: The cluster of differentiation (CD) is a nomenclature system that identifies and classifies cell surface antigens (2021 update); CD markers chart | Abcam (https://www.abcam.com/primary-antibodies/human-cd-antigen-guide)

4: U.S. Food and Drug Administration (FDA) approvals for the treatment of EBOV disease caused by ZEBOV, October 2020, Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award | Regeneron Pharmaceuticals Inc. (https://investor.regeneron.com/news-releases/news-releasedetails/inmazebtm-atoltivimab-maftivimab-and-odesivimab-ebgn-wins)

5: An overview of EBOV infection epidemiology from 1976 - 2022; Ebola Best Practice (https://bestpractice.bmj.com/topics/en-us/1210/epidemiology); Outbreaks | History | Ebola (Ebola Virus Disease) | CDC (https://www.cdc.gov/vhf/ebola/history/chronology.html)

6: 2015 Predictive values of EBOV rapid diagnostic tests (RDTs) and implications for decisionmakers.

(https://iris.who.int/bitstream/handle/10665/175554/WHO_EVD_HIS_EMP_15.2_annex_en g.pdf;jsessionid=84CD43A0220BE3C3E0E3A277741E7AE1?sequence=2)

7: 2023 Update on 11 Molecular Ebola virus diagnostics; Diagnostics of Ebola virus - PMC (nih.gov). (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995846/

8: Updates on 73 Molecular and Immunoassay Diagnostics: Directory for EBOV disease; Outbreaks test directory - FIND (finddx.org). (https://www.finddx.org/tools-andresources/dxconnect/test-directories/outbreaks-test-directory/)

9: A summary of all vaccines in development against EBOV infection; Overall Immunological Factors during EBOV Infection. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603231/)

10: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects | Global Health | JAMA | JAMA Network. (https://jamanetwork.com/journals/jama/fullarticle/1760318)

11: European Medicines Directive 2010/63/EU (https://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=celex:32010L0063) requires marketing authorisation holders to integrate, replace, reduce, and redefine (3Rs) welfare standards for the treatment of animals in all aspects of the development, manufacture and testing of medicines guidelines under Directive 201.0/63/EU; Ethical use of animals in medicine testing | European Medicines Agency (europa.eu). (https://www.ema.europa.eu/en/human-regulatory-overview/research-development/ethical-use-animals-medicine-testing)

12: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (https://www.ich.org/)

13: August 2023; Infection prevention and control guideline for Ebola and Marburg disease, August 2023 (https://www.who.int/publications/i/item/WHO-WPE-CRS-HCR-2023.1).

14: 2022 – 2023 Uganda declares end of Ebola disease outbreak | WHO | Regional Office for Africa (https://www.afro.who.int/countries/uganda/news/uganda-declares-end-ebola-disease-outbreak#:~:text=%E2%80%9CUganda%20put%20a%20swift%20end,and%20infection%2 C%20prevention%20and%20control)

15: Sudan ebolavirus - Nakisamata, complete genome (JN638998.1); National Library of Medicine, National Center for Biotechnology Information (NCBI); Sudan ebolavirus - Nakisamata, complete genome - Nucleotide - NCBI (nih.gov). (https://www.ncbi.nlm.nih.gov/nuccore/JN638998.1/)

16: Bundibugyo ebolavirus isolate (MK028856.1): Bundibugyo ebolavirus isolate Ebola virus/H.sapiens-tc/Uganda/2007/Bundibugyo-200706291, complete genome (nih.gov). (https://www.ncbi.nlm.nih.gov/nuccore/MK028856.1?report=graph)

17: Previous and current clinical trials; Search Results | Beta ClinicalTrials.gov. (https://clinicaltrials.gov/search?cond=ebola)

18: 2020 WHO makes new recommendations for Ebola treatments, calls for improved access. (https://www.who.int/news/item/19-08-2022-who-makes-new-recommendations-for-ebola-treatments-----calls-for-improved-access)

19: October 2023 Update: RedHill Biopharma - RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study. (https://www.redhillbio.com/news/news-details/2023/RedHill-and-U.S.-Army-Announce-Opaganibs-Ebola-Virus-Disease-Survival-Benefit-in-U.S.-Army-Funded-In-Vivo-Study/default.aspx)